| Similar Articles |
|---|
 |
The Motley Fool
January 15, 2008
Brian Orelli |
No Enhance-ment From Zetia Merck and Schering report bad news, but how much will it affect sales? Investors, take note.   |
The Motley Fool
November 22, 2010
Brian Orelli |
Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years. |
The Motley Fool
December 23, 2009
Brian Orelli |
Cancer Isn't Merck's Biggest Problem There's still hope for Merck's Vytorin, but investors will have to wait. |
The Motley Fool
November 16, 2009
Brian Orelli |
Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference. |
The Motley Fool
January 9, 2009
Brian Orelli |
Thanks for Nothing, FDA The Food and Drug Administration says there's still enough evidence that Merck and Schering-Plough's Vytorin works to warrant keeping patients on the drug. |
The Motley Fool
January 17, 2008
Michael P. Cecil |
2 Sources of Trouble for Vytorin You know that a drug study has gone very, very bad when you can't find out its results without a congressional inquiry. |
The Motley Fool
April 2, 2008
Michael P. Cecil |
Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite. |
The Motley Fool
May 22, 2008
Brian Orelli |
Merck Can't Achieve Anything The pharmaceutical cancels a troubled clinical trial. |
The Motley Fool
March 27, 2008
Brian Orelli |
I Heart the ACC What can investors expect from this weekend's blood-pumping American College of Cardiology scientific meeting? |
The Motley Fool
February 4, 2009
Brian Orelli |
The Tale of 2 Drugmakers Merck and Schering-Plough typically release earnings on the same day because they share sales of cholesterol drugs Vytorin and Zetia, but the drugmakers are far from the same. |
The Motley Fool
March 15, 2010
Brian Orelli |
Clinical Outcomes? Who Needs 'Em. Abbott's TriCor looks good on lab tests, but that's about all. |
The Motley Fool
March 31, 2008
Brian Orelli |
No Blood-Pumping Love for Merck and Schering From the reports coming out of the American College of Cardiology meeting, it looks like the drugmakers Merck and Schering-Plough took a beating. |
The Motley Fool
November 10, 2008
Brian Orelli |
Drug Fuels an Idling Rocket Ship AstraZeneca needs another FDA approval to really take advantage of its cholesterol drug's success. |
The Motley Fool
February 14, 2008
Brian Orelli |
A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product. |
The Motley Fool
December 1, 2009
Robert Steyer |
Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones. |
The Motley Fool
May 27, 2011
Brian Orelli |
AIM-HIGH? These Drugmakers Better Duck. A government study on cholesterol drugs hurts Abbott and Merck. |
The Motley Fool
April 2, 2008
Brian Lawler |
Bad Timing for AstraZeneca's Good Data AstraZeneca quietly reports a successful clinical study for its cholesterol-lowering lead drug. |
Chemistry World
February 19, 2013
Andrew Turley |
Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin). |
BusinessWeek
July 26, 2004
Amy Barrett |
Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents? |
The Motley Fool
April 29, 2008
Brian Orelli |
Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA. |
The Motley Fool
July 22, 2008
Brian Orelli |
Drug Duo SEAS Disappointment -- Again After numerous disappointments this year, Merck and Schering-Plough continue their string of bad luck. |
The Motley Fool
September 7, 2007
Brian Orelli |
Fighting the Generics Next Door Pfizer tries to stop patients from switching from it's patented Lipitor to generic Zocor by doing an observational study of patients on both medications. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
July 10, 2009
Brian Orelli |
Is the News Good or Bad? Who Cares! Sell! A trial comparing Merck's and Schering-Plough's cholesterol drug Zetia to Abbott Labs' Niaspan was ended early, causing a sell-off of Merck stock. |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
The Motley Fool
December 4, 2008
Brian Orelli |
Pfizer Blows Statin Smoke Pfizer presents some mildly persuasive numbers to try to win back customers for Lipitor. |
The Motley Fool
May 20, 2011
Brian Orelli |
Abbott Hits a Triple Not a home run, but Trilipix will likely stay on the market. |
The Motley Fool
March 9, 2009
Brian Orelli |
Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth. |
The Motley Fool
March 30, 2009
Brian Orelli |
To the Moon, Crestor? A few months ago, AstraZeneca released initial data showing how its cholesterol-lowering drug, Crestor, reduced the risk of heart attacks, strokes, and other heart-related issues by 44% in patients. Now it's back with more. |
The Motley Fool
April 18, 2011
Brian Orelli |
Up 95%! No Anchor Holding Amarin Down The second phase 3 trial of AMR101 deemed a success. |
The Motley Fool
November 30, 2010
Brian Orelli |
This Fish Oil Is No Snake Oil So far, Amarin's AMR101 looks like a wonder drug, and its potential is huge. |
The Motley Fool
December 4, 2006
Michael P. Cecil |
Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy? |
The Motley Fool
July 21, 2004
Brian Gorman |
Will Cholesterol Drug Pack a Punch? Merck's and Schering-Plough's new combination may receive a lukewarm welcome. In the near term, investors will probably cheer both companies, but in the long run, the companies will be better off it they can come up with something totally original. |
The Motley Fool
July 27, 2010
Brian Orelli |
Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant. |
The Motley Fool
July 18, 2008
Brian Orelli |
Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news. |
The Motley Fool
September 2, 2008
Brian Orelli |
Cardiologists Hate Vytorin Cardiologists seem cynical about the full presentation of Merck's and Schering-Plough's SEAS data at the European Society of Cardiology. |
The Motley Fool
August 2, 2004
Brian Gorman |
Will Lipitor's Certification Boost Pfizer? The FDA's ruling may help the company ward off a new threat. |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool
August 22, 2008
Brian Orelli |
Don't Worry About Vytorin's Cancer Risk While it doesn't seem that the investigations are likely to turn up anything, investors should at least keep up with the amount of news surrounding the Vytorin probe. |
The Motley Fool
December 16, 2008
Brian Orelli |
Doubling Up on Triple Lipid Drugs The Food and Drug Administration gave Abbott Lab's TriLipix the thumbs-up, approving it for use by itself or with statins. |
The Motley Fool
March 14, 2006
Brian Gorman |
AstraZeneca's Heartening News A new study shows cholesterol drug Crestor's further potential. Will it help sales? |
The Motley Fool
October 5, 2007
Brian Orelli |
Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note. |
The Motley Fool
December 30, 2003
Arash Mostaghimi |
Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects. |
The Motley Fool
October 21, 2008
Brian Orelli |
Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter. |
The Motley Fool
August 11, 2011
Brian Orelli |
Amarin Gets 1 Step Closer to the Big Time Amarin can start its outcomes study. The company announced yesterday that it had reached an agreement with the Food and Drug Administration to run an outcomes study for its fish oil drug, AMR101. |
The Motley Fool
November 18, 2009
Brian Orelli |
Drug Lowers Cholesterol; Stock Follows ISIS has a hard time at American Heart Association despite good efficacy data. |
The Motley Fool
October 9, 2008
Brian Orelli |
When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
June 30, 2008
Brian Orelli |
A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug. |
